With ageing, the potency of individual risk factors traditionally associated with common illnesses declines. Instead, it is becoming clear that the impact of a wide range of age-related deficits not traditionally considered as risk factors for these illnesses increases. These age-related deficits chiefly confer risk as a group, not individually. The many effects of age-related changes can be demonstrated epidemiologically, and in preclinical models, using a frailty index to distinguish between the contributions of traditional and non-traditional risk factors. Quantifying the contribution of age-related deficit accumulation in clinical and preclinical samples offers a powerful new tool for understanding mechanisms of age-related disease. It appears that a range of common late-life illnesses might be targeted by drugs aimed at ageing processes.
No takes yet. Share an insight, caveat, or question.
Rockwood et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: